CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer

Recruiting

• Conditions: Non-small Cell Lung Cancer
• Interventions: Biological: Serum and plasma samples

• Registration Number: NCT02764606
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

CANPOS is a non-interventional study aiming at evaluate at the time of initial surgery the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer. This would represent a rational to develop personalized follow-up and prevention strategies

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2013-11
• Study First Submitted: 2016-04-28
• Study First Submitted QC: 2016-05-05
• Study First Posted: 2016-05-06
• Status Verified: 2019-04
• Last Update Submitted: 2019-04-01
• Last Update Posted: 2019-04-02
• Primary Completion: 2025-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• patients with a diagnosis or suspected for a diagnosis of lung cancer, non-small cell lung cancer
• age over 18 years
• patient naïve of any oncology treatment (excluding surgery alone) within the past 5 years
• patient who signed the informed consent by the study protocol

Exclusion criteria were:

• any ongoing treatment for cancer
• any history of cancer within 5 years before the diagnosis of lung cancer
• any psychological, sociological or geographical conditions that would not allow the study follow-up

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with a non-small cell lung cancer	Serum and plasma samples	Serum and plasma samples (at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases).

Primary Outcome Measures

Name	Time	Method
The Serum levels of osteoprotegerin	At the time of initial surgery	The serum levels of osteoprotegerin, as assessed by standard ELISA methods, will be measured to to evaluate at the time of initial surgery, the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer.

Trial Locations

Locations (1)

Hospices Civils de Lyon / Hôpital Neurologique Pierre Wertheimer; 🇫🇷 Bron, France